Recent Quotes (30 days)

You have no recent quotes
chg | %

Aptose Biosciences Inc  

(Public, TSE:APS)   Watch this stock  
Find more results for TSE:LOR
6.65
+0.15 (2.31%)
Aug 27 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.65 - 6.80
52 week 5.00 - 9.14
Open 6.69
Vol / Avg. 9,613.00/20,313.00
Mkt cap 79.35M
P/E     -
Div/yield     -
EPS -1.25
Shares 11.93M
Beta 1.10
Inst. own     -
Aug 19, 2015
Aptose Biosciences Inc Annual Shareholders Meeting (Estimated)
Aug 13, 2015
Aptose Biosciences Inc at Canaccord Genuity Growth Conference - Webcast
Aug 4, 2015
Q2 2015 Aptose Biosciences Inc Earnings Call - Webcast
Aug 4, 2015
Q2 2015 Aptose Biosciences Inc Earnings Release
  

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.71% -
Return on average equity -51.64% -
Employees 17 -
CDP Score - -

Address

5955 Airport Road, Suite 228
MISSISSAUGA, ON ON L4V 1R9
Canada
+1-647-4799828 (Phone)
+1-416-7982200 (Fax)

Website links

Description

Aptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company's group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally, the Company has a preclinical small molecule program, APTO-500, targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company's large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).

Officers and directors

William Glenn Rice Chairman of the Board, President, Chief Executive Officer
Gregory Kwok Lee Chow Chief Financial Officer, Senior Vice President
Avanish Vellanki Senior Vice President, Chief Business Officer
Denis R. Burger Ph.D. Independent Director
Age: 70
Erich M. Platzer M.D.,Ph.D. Independent Director
Bradley Thompson Independent Director
Mark D. Vincent M.D. Independent Director
Warren Whitehead Independent Director